Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children (Q43647188)

25 November 2017

title

Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children (English)

1 reference

25 November 2017

1 reference

25 November 2017

Emonts M

1 reference

25 November 2017

de Bruijne EL

1 reference

25 November 2017

Guimarães AH

1 reference

25 November 2017

Leebeek FW

1 reference

25 November 2017

de Maat MP

1 reference

25 November 2017

Rijken DC

1 reference

25 November 2017

Hazelzet JA

1 reference

25 November 2017

Gils A

1 reference

25 November 2017

publication date

15 November 2007

1 reference

Journal of Thrombosis and Haemostasis

25 November 2017

published in

1 reference

25 November 2017

1 reference

25 November 2017

1 reference

25 November 2017

page(s)

268-276

1 reference

Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Serum lipids and disease severity in children with severe meningococcal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Transformations, means, and confidence intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Diagnosing meningococcemia as a cause of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Plasminogen-activator inhibitor type 1 and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

Why immunomodulatory therapies have not worked in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02841.X

10.1111/J.1538-7836.2007.02841.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference